Growing tumors face two major metabolic challenges-how to meet the bioenergetic and biosynthetic demands of increased cell proliferation, and how to survive environmental fluctuations in external nutrient and oxygen availability when tumor growth outpaces the delivery capabilities of the existing vasculature. Cancer cells display dramatically altered metabolic circuitry that appears to directly result from the oncogenic mutations selected during the tumorigenic process. An emerging theme in cancer biology is that many of the genes that can initiate tumorigenesis are intricately linked to metabolic regulation. In turn, it appears that a number of well-established tumor suppressors play critical roles in suppressing growth and/or proliferation when intracellular supplies of essential metabolites become reduced. In this review, we consider the potential role of tumor suppressors as metabolic regulators.
glycolysis for ATP production appears to be wasteful form of metabolism. Although the energetic yield per molecule of glucose is much lower for aerobic glycolysis compared with OXPHOS, when glucose is in excess and flux through the pathway high, glycolysis has the potential to produce ATP in greater quantities and at a faster rate (Guppy et al. 1993) . Metabolic pathways of growth and proliferation. Growth factor-independent activation of the PI3K/Akt and c-Myc pathways drives changes in cellular metabolism to promote cancer cell growth and proliferation. PI3K/Akt and c-Myc facilitate increased rates of glucose uptake and glycolysis. Lactate dehydrogenase (LDH-A) maintains glycolytic flux by converting excess pyruvate to lactate and regenerating NAD + in the process. Akt signaling promotes increased surface expression of the glucose transporter Glut1 and enhances the activity of glycolytic enzymes. Glucose (Glc) has multiple catabolic and biosynthetic fates, including glycolytic processing for production of ATP and pyruvate, processing through the pentose phosphate shunt to generate ribose 5-phosphate (Rib-5-P) and NADPH for nucleotide biosynthesis, or entry into the mitochondrion for biosynthesis or ATP generation by the TCA cycle and electron transport chain (ETC). Glucose-derived citrate (Cit) is exported to the cytosol and processed by ATP citrate lyase (ACL) to acetyl-CoA (Ac-CoA), which is channeled into lipid production. Glutamine (Gln) is deaminated to form glutamate, which can be processed further in the mitochondria by glutamate dehydrogenase (GDH) to In addition to energy, glycolysis generates metabolic intermediates important for cell growth. Metabolism of glucose through the oxidative or nonoxidative arms of the pentose phosphate pathway (PPP) generates ribose-5-phosphate (Rib-5-P), a key intermediate in nucleotide biosynthesis. The oxidative arm of the PPP can also produce NADPH, which supplies a pool of reducing equivalents for both nucleotide and fatty acid biosynthesis.
Recent data suggest that pyruvate kinase-M2 (PK-M2), an isoform of the rate-limiting enzyme for pyruvate generation that is preferentially expressed in tumor cells, regulates the flux of carbon into Rib-5-P and nucleotide synthesis (Christofk et al. 2008a) .
Interestingly, the enzymatic activity of PK-M2 is negatively regulated by phosphotyrosine signaling downstream from growth receptors (Christofk et al. 2008b) . By regulating the amount of pyruvate generated by glycolysis, PK-M2 functions to direct the flow of carbon into pathways of nucleotide and fatty acid biosynthesis that support the proliferation of tumor cells. Glycolytic intermediates including 3-phosphoglycerate (3-PG) serve as carbon sources for amino acid and lipid synthesis. Finally, pyruvate can be imported into the mitochondria and converted into substrates for the production of additional amino acids or fatty acid synthesis, and used to maintain mitochondrial membrane potential. Thus, maintaining high rates of glycolysis allows cells to meet the energetic and biosynthetic demands of anabolic growth.
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The mitochondrion-from engine to biosynthetic hub
The majority of macromolecules required for proliferation (i.e., lipids, proteins, and nucleic acids) are generated de novo from glucose (Bauer et al. 2005) . The remaining pyruvate from aerobic glycolysis that is not converted to lactate (∼10% of total) enters the mitochondrion and is extruded from the TCA cycle at various steps for use in biosynthetic pathways. Thus, in addition to its role as cellular energy center, the mitochondrion takes up a new role as a biosynthetic hub to meet the increased biosynthetic demand during proliferation, converting metabolites such as pyruvate and glutamine into intermediates utilized by other biosynthetic pathways (Fig. 1) . Despite the low overall percentage of pyruvate available for mitochondrial synthesis, the high rate of glycolytic flux provides sufficient amounts for biosynthesis.
Shunting of pyruvate into the TCA cycle generates a source of acetyl-CoA for the biosynthesis of lipids and amino acids. Acetyl-CoA condenses with oxaloacetate (OAA) to generate citrate, which is exported from the mitochondrion to the cytosol and converted back to acetyl-CoA by ATP citrate lyase (ACL). Inhibition of ACL results in decreased glucose-dependent lipid synthesis and impaired cell proliferation (Hatzivassiliou et al. 2005 ). This cytosolic pool of citrate-derived acetyl-CoA is essential for the synthesis of lipids (fatty acids, sphingomyelin, cholesterol, and isoprenoids). One risk of converting mitochondrial activity to biosynthesis is the loss of mitochondrial integrity due to depletion of TCA cycle intermediates. The export of citrate for lipid synthesis results in a net loss of OAA, the acceptor for pyruvate-derived acetyl-CoA, which must be regenerated to maintain the integrity of the TCA cycle. This can be achieved through the stepwise oxidation of glutamine in proliferating cells. Metabolic flux analysis has revealed that glutamine is used by proliferating cells to generate a pool of α-ketoglutarate, which can be metabolized through the TCA cycle to regenerate the OAA consumed by biosynthesis (DeBerardinis et al. 2007 ). This may explain why glutamine is an essential metabolite for proliferation (Griffiths and Keast 1990) . Given the importance of glutamine-mediated anapleurosis to TCA function and cell proliferation, regulators of this process are likely to possess oncogenic properties.
Tumor suppressors and oncogenes constitute metabolic signaling networks 
Metabolic adaptation by the AMPK Increased metabolic potential, while supportive of unchecked growth, poses a distinct metabolic challenge for tumor cells. Once a growing tumor outstrips its nutrient supply, it must enact strategies to maintain cellular bioenergetics (Fig. 2) . Thus, how tumors engage strategies of metabolic adaptation to survive stress may contribute to cancer progression and outcome (i.e., metastasis). Intracellular metabolic sensors represent key intersection points between the environment and physiology. The AMP-activated protein kinase (AMPK) is a highly conserved heterotrimeric protein kinase complex that plays a central role in the regulation of cellular energy homeostasis, tethering the bioenergetic state of a cell to a number of critical biological functions aimed at preserving cellular energy and viability (Hardie 2007) . AMPK was originally identified as a protein kinase allosterically regulated by AMP (Yeh et al. 1980) . AMPK is responsive to changes in the cellular AMP:ATP ratio and is activated by stresses that stimulate ATP consumption or inhibit ATP production (Hardie AMPK appears to function across evolution as a low energy checkpoint, triggering multiple biological adaptations designed to preserve energy and adapt to metabolic stress before the cell reaches a state of bioenergetic catastrophe that triggers cell death. In Saccharomyces cerevisiae, the yeast AMPK homolog Snf1 is essential for the metabolic shift required to grow on alternate or nonfermentable carbon sources (Carlson et al. 1981) . In (Fig. 3) . AMPK phosphorylates p53 at Ser-15, which stimulates both its transcriptional activity and initiates a metabolic cell cycle checkpoint (Jones et al. 2005) . This metabolic stress response is reinforced by the p53 target genes sestrin1 and sestrin2, which activate AMPK as part of a feedback loop 

p53 and metabolic control
p53 is a transcription factor that functions in a complex signaling network to mediate cellular adaptation to stress (Levine 1997) . In response to diverse cellular insults including DNA damage, hypoxia, and oxidative stress, p53 becomes post-translationally modified, which promotes both its stabilization and activation, and activates the expression of genes that induce cell cycle arrest, senescence, and apoptosis (Vogelstein et al. 2000) . Only recently has p53 been implicated in metabolic control, coordinating stress responses with changes in cellular metabolism and angiogenic potential (Fig. 4) . Activation of p53 by metabolic stress is driven by AMPK-dependent phosphorylation and influenced by mTOR Loss of p53-dependent regulation of SCO2 impairs the mitochondrial respiratory chain and promotes a switch in ATP production from OXPHOS to glycolysis. In addition, p53 activation has been reported to lead to the induction of potent anti-angiogenic factors that limit tumor growth (Teodoro et al. 2006) . Thus, in terms of metabolism, loss of p53 may provide a significant growth advantage to cancer cells. p53-deficient tumors engaged in aerobic glycolysis are able to more readily access energetic and biosynthetic pathways that support anabolic synthesis. By disengaging anti-angiogenic programs, p53 loss may rapidly promote greater access to nutrients to fuel these pathways. However, this growth advantage comes at a cost as loss of p53 renders cancer cells more sensitive to metabolic stress.
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Adaptation through oxygen sensing
Like nutrient depletion, reduced oxygen availability-hypoxia-stimulates metabolic adaptation in cells to promote energy production and reduce ATP consumption. Two major phenotypic consequences of hypoxia are increased glucose consumption and lactate production caused by a switch to anaerobic glycolysis. This metabolic shift is synchronized by hypoxia-inducible factor 1 (HIF1), a transcription factor complex activated by hypoxic stress (Gordan and Simon 2007; Semenza 2007) . Under normal oxygen tension, HIF1α accumulation is suppressed through modification by prolyl hydroxylation, which results in its ubiquitination by the von Hippel-Lindau (VHL) tumor suppressor and subsequent proteosomal degradation (Fig. 3) . Under low oxygen, prolyl hydroxylation of HIF1α is 
